NASDAQ:QUCY Mainz Biomed (QUCY) Stock Price, News & Analysis $1.15 -0.04 (-3.19%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock About Mainz Biomed Stock (NASDAQ:QUCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$1.12▼$1.1950-Day Range$0.32▼$3.5652-Week Range$0.30▼$4.93Volume121,396 shsAverage Volume9.36 million shsMarket Capitalization$16.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. Read More Mainz Biomed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreQUCY MarketRank™: Mainz Biomed scored higher than 5% of companies evaluated by MarketBeat, and ranked 93rd out of 95 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingMainz Biomed has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageMainz Biomed has only been the subject of 1 research reports in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 17.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.70% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently increased by 75.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.22 News SentimentMainz Biomed has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Mainz Biomed this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for QUCY on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows6 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Percentage Held by Insiders3.10% of the stock of Mainz Biomed is held by insiders.Percentage Held by InstitutionsMainz Biomed has minimal institutional ownership at this time.Read more about Mainz Biomed's insider trading history. Receive QUCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QUCY Stock News HeadlinesQuantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, ConnecticutJuly 16 at 4:05 PM | globenewswire.comQuantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone CorporationJuly 16 at 7:30 AM | globenewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.July 17 at 1:00 AM | Reagan Gold Group (Ad)Quantum Cyber Files for Drone Launch System Designed to Field Attritable Autonomous Drones at ScaleJuly 14 at 9:07 AM | globenewswire.comQuantum Cyber Completes Confidential Submission to U.S. Army ProgramJuly 8, 2026 | globenewswire.comQuantum Cyber Targets Annual Production Capacity of 100,000 Drones combining Kamikaze, Interceptor, Surveillance, VTOL and long-range Phantom 950 at Planned Bridgeport, Connecticut Manufacturing FacilityJuly 6, 2026 | globenewswire.comQuantum Cyber Addresses Short Seller Biased ReportJuly 6, 2026 | globenewswire.comQuantum Cyber Introduces PHANTOM-950 Long-Range Autonomous UAS Platform in DevelopmentJuly 2, 2026 | globenewswire.comSee More Headlines QUCY Stock Analysis - Frequently Asked Questions How have QUCY shares performed this year? Mainz Biomed's stock was trading at $0.7374 on March 13, 2026. Since then, QUCY shares have increased by 61.4% and is now trading at $1.19. How do I buy shares of Mainz Biomed? Shares of QUCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 3 weeks, QUCY's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QUCY CIK1874252 WebN/A Phone49 6131 5542860FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$540 thousand Price / Sales30.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book16.14Miscellaneous Outstanding Shares14,660,000Free Float14,207,000Market Cap$16.57 million OptionableN/A Beta2.28 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:QUCY) was last updated on 7/17/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
